Active substance
Sumatriptan
- SFDA 19
- US FDA 55
- EMA 1
- Health Canada 32
- US price lines 14
- NHS prices 8
- WHO EML 2
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| IMIGRAN | 50 mg | Tablet · Oral use | 6 Blister | SAR 100.85 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| IMIGRAN | 50 mg | Tablet · Oral use | 2 Blister | SAR 38.30 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| IMIGRAN | 100 mg | Tablet · Oral use | 6 Blister | SAR 150.05 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| IMIGRAN | 100 mg | Tablet · Oral use | 2 Blister | SAR 57.00 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| IMIGRAN 20 MG NASAL SPRAY | 20 mg | Nasal spray · Nasal use | 2 Nasal Applicator | SAR 38.20 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| IMIGRAN 6MG-0.5ML AMP | 12 mg/ml | Solution · Subcutaneous use | 1 Pre-filled syringe | SAR 125.50 | NCE · Prescription | Glaxo Saudi Arabia Ltd | Valid |
| ORATAB 100 mg | 100 mg | Film-coated tablet · Oral use | 6 Blister | SAR 128.60 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| ORATAB 100MG F.C. TABLETS | 100 mg | Film-coated tablet · Oral use | 2 Blister | SAR 49.85 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| SUMAREX 100 MG F.C.TABLET (2S) | 100 mg | Film-coated tablet · Oral use | 2 Blister | SAR 40.35 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| SUMAREX 100 MG F.C.TABLET (6S) | 100 mg | Film-coated tablet · Oral use | 6 Blister | SAR 104.15 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| SUMAREX 50 MG F.C.TABLET (2S) | 50 mg | Film-coated tablet · Oral use | 2 Blister | SAR 30.20 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| SUMAREX 50 MG F.C.TABLET (6S) | 50 mg | Film-coated tablet · Oral use | 6 Blister | SAR 79.40 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| IMIGRAN 10 MG NASAL SPRAY | 10 mg | Nasal spray · Nasal use | 2 Nasal Applicator | SAR 29.85 | NCE · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
| IMIGRAN 10 MG NASAL SPRAY | 10 mg | Nasal spray · Nasal use | 2 Nasal Applicator | SAR 23.90 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Withdrawn by MAH · Not Marketed |
| IMIGRAN 20 MG NASAL SPRAY | 20 mg | Nasal spray · Nasal use | 2 Nasal Applicator | SAR 47.75 | NCE · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
| MIGRABAN 100MG FILM COATED TABLETS | 100 mg | Film-coated tablet · Oral use | 2 Blister | SAR 44.85 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| MIGRABAN 100MG FILM COATED TABLETS | 100 mg | Film-coated tablet · Oral use | 6 Blister | SAR 115.75 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| MIGRABAN 50MG FILM COATED TABLETS | 50 mg | Film-coated tablet · Oral use | 2 Blister | SAR 33.55 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| MIGRABAN 50MG FILM COATED TABLETS | 50 mg | Film-coated tablet · Oral use | 6 Blister | SAR 88.25 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
MIGRAINE/ HEADACHE; NAUSEA AND VOMITING IN CYCLIC VOMITING SYNDROME; POLYCYTHEMIA VERA - MIGRAINES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| IMITREX STATDOSE (AUTOINJECTOR) | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML); EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | GLAXOSMITHKLINE | Prescription | 28 Dec 1992 |
| IMITREX | EQ 100MG BASE; EQ 25MG BASE; EQ 50MG BASE | tablet · oral | GLAXOSMITHKLINE | Prescription | 1 Jun 1995 |
| IMITREX | 5MG/SPRAY; 20MG/SPRAY | spray · nasal | GLAXOSMITHKLINE | Prescription | 26 Aug 1997 |
| SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | WOCKHARDT BIO AG | Prescription | 6 Feb 2009 |
| SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | HIKMA PHARMS | Prescription | 6 Feb 2009 |
| SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | FRESENIUS KABI USA | Prescription | 2 Mar 2009 |
| SUMATRIPTAN SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet · oral | DR REDDYS LABS INC | Prescription | 10 Aug 2009 |
| SUMATRIPTAN SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet · oral | WATSON LABS | Prescription | 10 Aug 2009 |
| SUMATRIPTAN SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet · oral | MYLAN | Prescription | 10 Aug 2009 |
| SUMATRIPTAN SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet · oral | ORBION PHARMS | Prescription | 10 Aug 2009 |
| SUMATRIPTAN SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 10 Aug 2009 |
| SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | ONESOURCE SPECIALTY | Prescription | 10 Jun 2010 |
| SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | SUN PHARM | Prescription | 21 Jun 2011 |
| SUMATRIPTAN SUCCINATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE | tablet · oral | ZHEJIANG | Prescription | 19 Jun 2012 |
| SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | EUGIA PHARMA | Prescription | 23 Apr 2013 |
| SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | HIKMA | Prescription | 16 Sep 2013 |
| SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | solution · subcutaneous | DR REDDYS | Prescription | 29 Jan 2014 |
| ONZETRA XSAIL | EQ 11MG BASE | powder · nasal | AZURITY | Prescription | 27 Jan 2016 |
| ZEMBRACE SYMTOUCH (AUTOINJECTOR) | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | solution · subcutaneous | TONIX MEDS | Prescription | 28 Jan 2016 |
| SUMATRIPTAN | 5MG/SPRAY; 20MG/SPRAY | spray · nasal | LANNETT CO INC | Prescription | 19 Feb 2016 |
| TOSYMRA | 10MG/SPRAY | spray · nasal | TONIX MEDS | Prescription | 25 Jan 2019 |
| SUMATRIPTAN | 20MG/SPRAY; 5MG/SPRAY | spray · nasal | PADAGIS ISRAEL | Prescription | 21 Sep 2020 |
| SUMATRIPTAN | 5MG/SPRAY | spray · nasal | PERRIGO UK FINCO | Prescription | 21 Sep 2020 |
| SUMATRIPTAN | 20MG/SPRAY | spray · nasal | REGCON HOLDINGS | Prescription | 17 Feb 2021 |
| SUMATRIPTAN | 20MG/SPRAY | spray · nasal | CIPLA | Prescription | 22 Feb 2021 |
30 more — full table
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-SUMATRIPTAN | 02268388 | 50 MG | TABLET · ORAL | APOTEX INC |
| APO-SUMATRIPTAN | 02268396 | 100 MG | TABLET · ORAL | APOTEX INC |
| IMITREX | 02212188 | 6 MG / 0.5 ML | SOLUTION · SUBCUTANEOUS | GLAXOSMITHKLINE INC |
| IMITREX | 02230418 | 5 MG / ACT | SPRAY · NASAL | GLAXOSMITHKLINE INC |
| IMITREX | 02230420 | 20 MG / ACT | SPRAY · NASAL | GLAXOSMITHKLINE INC |
| IMITREX DF - TAB 100MG | 02212161 | 100 MG | TABLET · ORAL | GLAXOSMITHKLINE INC |
| JAMP SUMATRIPTAN | 02545349 | 25 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP SUMATRIPTAN | 02545357 | 50 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP SUMATRIPTAN | 02545365 | 100 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP SUMATRIPTAN DF | 02545292 | 25 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP SUMATRIPTAN DF | 02545306 | 50 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP SUMATRIPTAN DF | 02545314 | 100 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MYLAN-SUMATRIPTAN | 02268906 | 25 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-SUMATRIPTAN | 02268914 | 50 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-SUMATRIPTAN | 02268922 | 100 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| PMS-SUMATRIPTAN | 02256428 | 25 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-SUMATRIPTAN | 02256436 | 50 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-SUMATRIPTAN | 02256444 | 100 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PRO-SUMATRIPTAN | 02324652 | 50 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PRO-SUMATRIPTAN | 02324660 | 100 MG | TABLET · ORAL | PRO DOC LIMITEE |
| SUMATRIPTAN | 02286521 | 50 MG | TABLET · ORAL | SANIS HEALTH INC |
| SUMATRIPTAN | 02286548 | 100 MG | TABLET · ORAL | SANIS HEALTH INC |
| SUMATRIPTAN | 02546035 | 50 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| SUMATRIPTAN | 02546043 | 100 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| SUMATRIPTAN DF | 02385570 | 50 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
7 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | IMITREX 100 MG TABLET | $72.39673 | per EA | 23 Sep 2026 |
| US NADAC | IMITREX 4 MG/0.5 ML PEN INJECT | $463.07333 | per ML | 23 Sep 2026 |
| US NADAC | IMITREX 6 MG/0.5 ML CARTRIDGES | $436.79714 | per ML | 23 Sep 2026 |
| US NADAC | IMITREX 6 MG/0.5 ML PEN INJECT | $460.05429 | per ML | 23 Sep 2026 |
| US NADAC | SUMATRIPTAN 20 MG NASAL SPRAY | $16.5061 | per EA | 23 Sep 2026 |
| US NADAC | SUMATRIPTAN 5 MG NASAL SPRAY | $17.03859 | per EA | 23 Sep 2026 |
| US NADAC | SUMATRIPTAN 6 MG/0.5 ML AUTOINJ | $61.41234 | per ML | 23 Sep 2026 |
| US NADAC | SUMATRIPTAN 6 MG/0.5 ML VIAL | $15.0 | per ML | 2 Sep 2026 |
| US NADAC | SUMATRIPTAN 6 MG/0.5 ML VIAL | $14.93447 | per ML | 23 Sep 2026 |
| US NADAC | SUMATRIPTAN SUCC 100 MG TABLET | $0.43878 | per EA | 23 Sep 2026 |
| US NADAC | SUMATRIPTAN SUCC 25 MG TABLET | $0.23942 | per EA | 23 Sep 2026 |
| US NADAC | SUMATRIPTAN SUCC 50 MG TABLET | $0.30222 | per EA | 30 Sep 2026 |
| NHS Drug Tariff | Sumatriptan 100mg tablets | £2.10 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sumatriptan 10mg/0.1ml nasal spray unit dose | £14.16 | 2 unit dose | 1 Oct 2026 |
| NHS Drug Tariff | Sumatriptan 20mg/0.1ml nasal spray unit dose | £42.47 | 6 unit dose | 1 Oct 2026 |
| NHS Drug Tariff | Sumatriptan 3mg/0.5ml solution for injection pre-filled disposable devices | £39.50 | 2 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Sumatriptan 50mg tablets | £4.24 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sumatriptan 6mg/0.5ml solution for injection pre-filled disposable devices | £43.56 | 2 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Sumatriptan 6mg/0.5ml solution for injection pre-filled syringes with device | £50.96 | 2 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Sumatriptan 6mg/0.5ml solution for injection syringe refill | £48.49 | 2 pre-filled disposable injection | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.1.5.3. Medicines for cluster headache · core
Trigeminal autonomic cephalalgias
Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe - 5.1.5.1. Medicines for acute migraine attacks · core
Migraine
Oral > Solid > tablet: 50 mg
Safety signals and safety-related labeling changes
- US FDA 9 Dec 2025 IMITREX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Dec 2025 IMITREX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Dec 2025 IMITREX STATDOSE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Dec 2025 IMITREX — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 TREXIMET — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 2 Jul 2020 SUMAVEL DOSEPRO — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 10 Jun 2019 ZEMBRACE SYMTOUCH — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Sumatriptan
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.